SIGLEC10 and neoplasm: In our study, the treatment of 4T1 tumor models using OAd-Siglec10-Fc combined with anti-PD-1, which targets both TAMs and T cells, was found to be a reasonable and promising strategy that altered the antitumor immune response, promoted phagocytosis by macrophages and enhanced the effects of subsequent treatment with ICIs.